MedTrace Logo

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00364676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2015-09-22

No results posted yet for this study

Summary

This Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease.

Conditions

  • Tumors
  • Hodgkins Disease
  • Non-Hodgkins Lymphoma

Interventions

DRUG

VLI

Patients are dosed on Day 1 and Day 8 of a 21-day cycle.

DRUG

VLI

Patients are dosed on Day 1 of a 21-day cycle.

Sponsors & Collaborators

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • John Sarantopoulos, MD · Cancer Therapy and Research Center, Texas

  • Gerald Batist, MD · McGill Centre for Translational Research in Cancer-Jewish General Hospital Clinical Research Unit

  • Anthony W. Tolcher, MD · South Texas Accelerated Research Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2015-06-30
Completion
2015-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00364676 on ClinicalTrials.gov